Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343187 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00343187 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 2 participants.
The verdict
NCT00343187, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of ACZONE in subjects treated with the HER1/EGFR inhibitor Tarceva (erlotinib) who develop a rash on the face
Interventions
- DRUG Vehicle Control
- DRUG ACZONE (dapsone) Gel, 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343187
The ClinicalTrials.gov registry entry for NCT00343187 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Control is the first listed.
NCT00343187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343187 about?
NCT00343187 is a clinical study titled "A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash". The purpose of this study is to evaluate the safety and preliminary efficacy of ACZONE in subjects treated with the HER1/EGFR inhibitor Tarceva (erlotinib) who develop a rash on the face
What is the current status of trial NCT00343187?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2006-06. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00343187?
The interventions under investigation include: Vehicle Control (DRUG), ACZONE (dapsone) Gel, 5% (DRUG).
Who is sponsoring clinical trial NCT00343187?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.